Over recent months, a striking pattern has emerged: major capital allocators are positioning around AI-driven biology and longevity. According to a Polymarket post on X, Coinbase (NASDAQ:COIN | COIN Price Prediction) founder Brian Armstrong’s longevity startup NewLimit has tripled in value to $3.1 billion. That post sparked a viral reply thread from podcast host Mgoes (@m_goes_distance), cataloging billionaire and corporate bets on programmable biology.
For enterprising investors, the hook is simple. When visionary billionaires and blue-chip operators converge on the same theme, it’s worth understanding what they see. Most named startups are privately held, leaving NVIDIA (NASDAQ:NVDA) and Eli Lilly (NYSE:LLY) as the two realistic public-market entry points.
The Verified Anchor: NVIDIA’s $1 Billion Bet With Eli Lilly
In January, NVIDIA and Eli Lilly announced a first-of-its-kind AI co-innovation lab, committing up to $1 billion over five years to industrialize drug discovery, with the lab based in the San Francisco Bay Area and running on NVIDIA’s BioNeMo platform and Vera Rubin architecture. Eli Lilly also built the “LillyPod” supercomputer with NVIDIA GPUs to accelerate drug discovery.
The buildout is structural. NVIDIA CEO Jensen Huang has called the broader AI buildout “the largest infrastructure expansion in human history,” and pharma is increasingly part of that buildout.
The Mgoes Thread: Big Claims, Unverified
The viral X reply by Mgoes goes further. According to the Mgoes post, Amazon (NASDAQ:AMZN) founder Jeff Bezos put $3 billion behind Altos Labs, DeepMind Technologies CEO Demis Hassabis raised $2.1 billion for Isomorphic Labs, and Anthropic acquired Coefficient Bio for $400 million (I have not independently verified those figures).
Mgoes also asserts that longevity biotech raised $3.74 billion in Q1 2026, which the post claims is 56% ahead of Q1 2025 (again, I haven’t verified these figures), framing the thesis as “biotech is starting to move like AI did 3 years ago” with the smart money positioning rather than speculating. Even if the specific dollar figures are debatable, the corporate footprint around NVIDIA’s BioNeMo ecosystem is certainly notable.
The Two Investable Names
NewLimit, Altos Labs, Isomorphic Labs, and Coefficient Bio are all privately held. Hence, NVIDIA and Eli Lilly become the practical vehicles for this theme.
NVIDIA is the picks-and-shovels play. Its BioNeMo platform and the Eli Lilly lab make it the compute backbone of programmable biology, and the underlying business is firing on every cylinder. NVIDIA’s Q1 FY2027 revenue hit $81.615 billion, up 85% year over year, with non-GAAP gross margin of 75% and free cash flow of $48.554 billion in the quarter; NVDA stock is up 16% year to date.
Eli Lilly offers the blue-chip applied-biology angle. The company’s Q1 2026 revenue came in at $19.8 billion, up 56% year over year, with non-GAAP EPS of $8.55, and management raised full-year guidance to $82 billion to $85 billion in revenue. Mounjaro and Zepbound prove Eli Lilly can monetize a single therapeutic category at extraordinary scale, which is exactly the playbook AI-discovered drugs could one day replicate.
The Honest Takeaway
The convergence of Bezos-tier visionaries and blue-chip operators on AI-biology is real, even if the dollar figures from the Mgoes thread remain unverified. However, neither public name is cheap: Eli Lilly trades at a P/E ratio of 38x, and NVIDIA at a P/E ratio of 34x.
For investors seeking exposure to programmable biology without underwriting private startup risk, NVDA and LLY stock are the realistic public vehicles. Use the smart-money signal as a reason to study the theme carefully, sizing your positions according to your own risk tolerance rather than chasing it.
Top Gaining Stocks
Top Losing Stocks